Stent maker Boston Scientific Corporation (NYSE:BSX) hit expectations with its third quarter profits, while revenues beat Wall Street forecasts.
Earnings for the three months ended September 30 rose to US$283mln or 20 cents a share, from US$228mln or 17 cents in the same period of 2016.
Adjusted earnings per share totalled 31 cents, matching what analysts had expected.
Revenues increased to US$2.22bn from US$2.11bn a year earlier, just ahead of the consensus estimate of US$2.21bn.
“Our global team is delivering strong performance as we continue to invest in a deep and innovative portfolio and expand into faster-growing markets,” said chairman and chief executive Mike Mahoney.
“We are grateful for our employees’ commitment and winning spirit, particularly our team in Puerto Rico, which is working hard to address customer and patient needs in the wake of the recent hurricanes.”
Shares were down 2.5% to US$28.86.